… of a $500 million initial public offering (IPO) and said that it … approved anti-angiogenic therapies.  Regulus Therapeutics  Developing antisense oligonucleotides to … placement in March 2024 Regulus Therapeutics is developing antisense oligonucleotide …

… F2 and F3 fibrosis stages. Regulus Therapeutics Inc. (NASDAQ: RGLS) will present … autosomal dominant polycystic kidney disease. IPO Elevation Oncology, Inc., a clinical … genomically defined cancers, priced its initial public offering of 6.25 million shares …

… witnessed a host of an initial public offering, as IPO news flow resumed after … the progression of symptoms (Thursday) Regulus Therapeutics Inc (NASDAQ: RGLS): Data from … for transthyretin amyloidosis (Saturday) IPOs IPO Pricings Miromatrix Medical Inc., a …

… Health Inc (NASDAQ: RDUS) Regulus Therapeutics Inc (NASDAQ: RGLS) Salarius … (after the market close) IPOs French clinical-stage biotech Biophytis … with aging, priced its initial public offering of 1.2 million … system disorders, priced its IPO of $2.25 million …

… : NK) Penumbra Inc (NYSE: PEN) Regulus Therapeutics Inc (NASDAQ: RGLS) Rubius Therapeutics … . (NYSE: RMD) (after the close) IPOs Raritan, New Jersey-based Ortho … Diagnostics Holdings plc priced its initial public offering of 76 million ordinary shares …

… HealthCare Partners Inc. (DVA), and Regulus Therapeutics (RGLS), among others. He claims … to the prospectus, after the IPO, TCR2 Therapeutics expects to have … use the money from the IPO to pay debt or … -300 million right after the IPO. With this in mind, …

… Source: Prospectus After the IPO, the equity structure is … . Most investors look for IPOs like that of Moderna, … cash equivalents after the IPO. Investors will appreciate that … . Source: ArrowHeadPharma’s Website Regulus Therapeutics (RGLS) is very small …